He has not been able to speak since 2003, when he was paralyzed at age 20 by a severe stroke after a terrible car crash.
Now, in a scientific milestone, researchers have tapped into the speech areas of his brain — allowing him to produce comprehensible words and sentences simply by trying to say them. When the man, known by his nickname, Pancho, tries to speak, electrodes implanted in his brain transmit signals to a computer that displays his intended words on the screen.
His first recognizable sentence, researchers said, was, “My family is outside.”
Investing in the convergence of bioelectrics & biologics for regeneration & healing — howard J. leonhardt, founder, leonhardt ventures.
Howard Leonhardt is the Founder of Leonhardt Ventures, the world’s first Innovation Accelerator focused on the convergence of bioelectrics & biologics for organ regeneration and tissue healing.
Howard is an accomplished inventor and serial entrepreneur, with 21 U.S. patents, over 100 patent claims for products for treating cardiovascular disease, and has over 40 new patent claims pending. His TALENT (Taheri-Leonhardt) stent graft, developed in the early 1990′s, holds a leading world market share for repairing aortic aneurysms without surgery.
Howard’s inventions to date have been involved in treated over 500000 patients in 60 countries.
Howard is co-leader of Startup California and Founder and Chairman of The California Stock Exchange TM (Cal-X) preparing to be the first social good impact stock exchange currently operating the Cal-X 30 Social Good Impact fund. He founded Cal-X Crowdfund Connect, a crowdfunding campaign management company, and Cal-X Stars Business Accelerator, Inc., a business incubator and accelerator focused on cardiovascular life sciences and social good impact innovations.
There are 30 regenerative med-tech and regenerative economy startups in his current portfolio. His Leonhardt Ventures angels network has raised and put to work over US$145 million in 32 companies to date, including those developing the first implantable programmable and re-fillable stem cell pump, brain, eye, and aorta regeneration technologies, and number of other organ regeneration spin offs from his patented core technologies.
Howard Leonhardt serves as state spokesperson in California for the JOBS ACT and Crowdfunding for Startup California and has given over 40 speeches on the subject. He has operated Leonhardt’s Launchpads NorCal at the University of Northern California Science & Technology Innovation Center in Rohnert Park, CA since 2008 and recently opened Leonhardt’s Launchpads Utah in Salt Lake City just off the campus of the University of Utah. He has served on the Board of Directors of the University of Northern California, a private biomedical engineering school, since 1999.
NAD Coenzymes, Metabolic Stress, And Novel Preventative And Therapeutic Interventions — Dr. Charles Brenner, Ph.D., City of Hope.
Dr. Charles Brenner Ph.D. is the Alfred E Mann Family Foundation Chair in Diabetes and Cancer Metabolism, and Professor and Chair of the Department of Diabetes & Cancer Metabolism, at the City of Hope Comprehensive Cancer Center (https://www.cityofhope.org/faculty/charles-brenner).
With his Ph.D. in Cancer Biology from Stanford University, Dr. Brenner’s laboratory focuses on disturbances in nicotinamide adenine dinucleotide (NAD), the central catalyst of metabolism, in diseases and conditions of metabolic stress (https://www.cityofhope.org/charles-brenner-lab).
Among his most significant discoveries, Dr. Brenner identified nicotinamide riboside (NR) as a vitamin precursor of NAD, as well as a quantitative metabolomic technology that allowed him to discover that the NAD system is disturbed by many diseases and conditions of metabolic stress, including diabetes and cancer.
Specifically, Dr. Brenner and colleagues have found that in animal models of fatty liver, type 2 diabetes, diabetic and chemotherapeutic neuropathy, central brain injury, heart failure, postpartum and coronavirus infection, the NAD system is disturbed and that in these models, provision of nicotinamide riboside is highly protective.
Dr. Brenner also led the team that conducted the first clinical trial of nicotinamide riboside establishing safe oral availability and has participated in trials establishing safety and potential activities of nicotinamide riboside in clearance of liver fat and depression of common markers of inflammation.
Dr. Brenner continues to research how the NAD system is disregulated as a function of postpartum, coronavirus infection, inflammatory conditions, diabesity and specific malignancies, with the dual goals of defining mechanisms of biological regulation and developing safe preventative and therapeutic interventions for people.
Dr. Brenner’s work over the years been funded by numerous agencies including the Leukemia & Lymphoma Society, the March of Dimes, the Burroughs Wellcome Fund, the Beckman Foundation, the Lung Cancer Research Foundation, the National Institutes of Health, and the National Science Foundation.
We have a much better understanding of physics than we do of consciousness. I consider ways in which intrinsically mental aspects of fundamental ontology might induce modifications of the known laws of physics, or whether they could be relevant to accounting for consciousness if no such modifications exist. I suggest that our current knowledge of physics should make us skeptical of hypothetical modifications of the known rules, and that without such modifications it’s hard to imagine how intrinsically mental aspects could play a useful explanatory role. Draft version of a paper submitted to Journal of Consciousness Studies, special issue responding to Philip Goff’s Galileo’s Error: Foundations for a New Science of Consciousness.
Interested in living longer? You are probably going to get TPE at some point. The Conboys are looking for funding for human trials to produce a product in 3–4 years. Here we have infor on what it is and how it works plus actual human results to date (starting at 10 minutes).
In Part III, Dr Kiprov, discusses the history of moving from the Conboy’s experiments in the lab to the process used in the clinic and reasons for the choices made. He also covers the benefits that he has seen with plasma exchange in the clinic.
Part I Video Link https://youtu.be/jpJlgSzRdyo. Part II Video Link https://youtu.be/P0j96lU9_-g.
Dr Dobri Kiprov is internationally recognized as a pioneer and a leading expert in the field of Therapeutic Apheresis. He is Chief of the Division of Immunotherapy at California Pacific Medical Center in San Francisco, California and Medical Director of Apheresis Care Group (ACG).
Dr Kiprov has been working with the Drs Conboy for many years on plasma exchange and recently they published a joint paper based on their experience in the clinic and the laboratory.
Dobri Kiprov, M.D., H.P. (ASCP) — Home page. https://dobrikiprov.com/
Some examples papers from Dr Kiprov. Therapeutic plasma exchange (TPE) and blood products — Implications for longevity and disease. https://pubmed.ncbi.nlm.nih.gov/34074614/ Attenuation of age-elevated blood factors by repositioning plasmapheresis: A novel perspective and approach. https://pubmed.ncbi.nlm.nih.gov/34083162/ A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer’s disease: Primary results of the AMBAR Study. https://pubmed.ncbi.nlm.nih.gov/32715623/
************************************************************ Health claims Disclosure: Information provided on this video is not a substitute for direct, individual medical treatment or advice. Please consult with your doctor first. Products or services mentioned in this video are not a recommendation.
Researchers at UC San Francisco have successfully developed a “speech neuroprosthesis” that has enabled a man with severe paralysis to communicate in sentences, translating signals from his brain to the vocal tract directly into words that appear as text on a screen.
The achievement, which was developed in collaboration with the first participant of a clinical research trial, builds on more than a decade of effort by UCSF neurosurgeon Edward Chang, MD, to develop a technology that allows people with paralysis to communicate even if they are unable to speak on their own. The study appears July 15 in the New England Journal of Medicine.
Summary: Aromatic turmerone, a compound derived from turmeric essential oil, and its derivatives directly affect dopamine neurons to generate neuroprotective properties in tissue culture models of Parkinson’s disease.
Source: Kumamoto University.
Researchers from Kumamoto University, Japan have found that a component derived from turmeric essential oil, aromatic turmerone (ar-turmerone), and its derivatives act directly on dopaminergic nerves to create a neuroprotective effect on tissue cultures of a Parkinson’s disease model.
In a medical first, researchers harnessed the brainwaves of a paralyzed man unable to speak and turned what he intended to say into sentences on a computer screen.
Study marks important step toward restoring more natural communication for people who can’t talk.
Summary: Using human stem cells to develop a brain organoid model, researchers were able to show exposure to a common pesticide synergizes with an autism-linked gene mutation. The study provides clear evidence that genetics and environment may combine to disrupt neurodevelopment.
Source: Johns Hopkins University.
Researchers at Johns Hopkins Bloomberg School of Public Health have shown in a brain organoid study that exposure to a common pesticide synergizes with a frequent autism-linked gene mutation.
